200 related articles for article (PubMed ID: 8621930)
1. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
2. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.
Toes RE; Offringa R; Blom RJ; Brandt RM; van der Eb AJ; Melief CJ; Kast WM
J Immunol; 1995 Apr; 154(7):3396-405. PubMed ID: 7534797
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.
Toes RE; van der Voort EI; Schoenberger SP; Drijfhout JW; van Bloois L; Storm G; Kast WM; Offringa R; Melief CJ
J Immunol; 1998 May; 160(9):4449-56. PubMed ID: 9574550
[TBL] [Abstract][Full Text] [Related]
4. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells.
Toes RE; Blom RJ; van der Voort E; Offringa R; Melief CJ; Kast WM
Cancer Res; 1996 Aug; 56(16):3782-7. PubMed ID: 8706024
[TBL] [Abstract][Full Text] [Related]
5. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.
Toes RE; Offringa R; Blom RJ; Melief CJ; Kast WM
Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7855-60. PubMed ID: 8755566
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.
Feltkamp MC; Smits HL; Vierboom MP; Minnaar RP; de Jongh BM; Drijfhout JW; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1993 Sep; 23(9):2242-9. PubMed ID: 7690326
[TBL] [Abstract][Full Text] [Related]
7. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
[TBL] [Abstract][Full Text] [Related]
8. Successful immunotherapy of an intraocular tumor in mice.
Schurmans LR; den Boer AT; Diehl L; van der Voort EI; Kast WM; Melief CJ; Toes RE; Jager MJ
Cancer Res; 1999 Oct; 59(20):5250-4. PubMed ID: 10537305
[TBL] [Abstract][Full Text] [Related]
9. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection.
Newmaster RS; Mylin LM; Fu TM; Tevethia SS
Virology; 1998 May; 244(2):427-41. PubMed ID: 9601511
[TBL] [Abstract][Full Text] [Related]
10. Tumor agonist peptides break tolerance and elicit effective CTL responses in an inducible mouse model of hepatocellular carcinoma.
Stahl S; Sacher T; Bechtold A; Protzer U; Ganss R; Hämmerling GJ; Arnold B; Garbi N
Immunol Lett; 2009 Mar; 123(1):31-7. PubMed ID: 19428549
[TBL] [Abstract][Full Text] [Related]
11. Resistance to polyoma virus-induced tumors correlates with CTL recognition of an immunodominant H-2Dk-restricted epitope in the middle T protein.
Lukacher AE; Wilson CS
J Immunol; 1998 Feb; 160(4):1724-34. PubMed ID: 9469430
[TBL] [Abstract][Full Text] [Related]
12. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.
Franke ED; Corradin G; Hoffman SL
J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors.
Feltkamp MC; Vreugdenhil GR; Vierboom MP; Ras E; van der Burg SH; ter Schegget J; Melief CJ; Kast WM
Eur J Immunol; 1995 Sep; 25(9):2638-42. PubMed ID: 7589138
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
Schirmbeck R; Böhm W; Reimann J
J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
[TBL] [Abstract][Full Text] [Related]
15. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
Thomson SA; Sherritt MA; Medveczky J; Elliott SL; Moss DJ; Fernando GJ; Brown LE; Suhrbier A
J Immunol; 1998 Feb; 160(4):1717-23. PubMed ID: 9469429
[TBL] [Abstract][Full Text] [Related]
16. Protection against lethal viral infection by vaccination with nonimmunodominant peptides.
Oukka M; Manuguerra JC; Livaditis N; Tourdot S; Riche N; Vergnon I; Cordopatis P; Kosmatopoulos K
J Immunol; 1996 Oct; 157(7):3039-45. PubMed ID: 8816413
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
Gabrilovich DI; Ciernik IF; Carbone DP
Cell Immunol; 1996 May; 170(1):101-10. PubMed ID: 8665590
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
19. Induction of murine cytotoxic T lymphocytes against Plasmodium falciparum sporozoite surface protein 2.
Wizel B; Rogers WO; Houghten RA; Lanar DE; Tine JA; Hoffman SL
Eur J Immunol; 1994 Jul; 24(7):1487-95. PubMed ID: 7517870
[TBL] [Abstract][Full Text] [Related]
20. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
